A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework.
Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view.
The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response